Newgenivf Group LTD (NIVFW) — SEC Filings

Q: What are the key financial highlights for Newgenivf Group LTD?

Key financial highlights for Newgenivf Group LTD are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Newgenivf Group LTD?

Key executives at Newgenivf Group LTD are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Newgenivf Group LTD stock?

Risk factors for Newgenivf Group LTD (NIVFW) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Newgenivf Group LTD?

Forward-looking statements and predictions from Newgenivf Group LTD are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Newgenivf Group LTD. Recent 6-K filing on Dec 2, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Newgenivf Group LTD on SEC EDGAR

Overview

Newgenivf Group LTD (NIVFW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 2, 2025: NewGenIvf Group Limited filed a Form 6-K on December 2, 2025, reporting its nine-month results for 2025. The company, formerly known as ASPAC I Mini Acquisition Corp., is based in Bangkok, Thailand, and is a foreign private issuer. The filing includes Exhibit 99.1, which details the company's financ

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 1 bearish, 39 neutral, 1 mixed. The dominant filing sentiment for Newgenivf Group LTD is neutral.

Filing Type Overview

Newgenivf Group LTD (NIVFW) has filed 32 6-K, 1 20-F/A, 3 20-F, 3 SC 13G, 1 SC 13D, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (41)

NewGenIvf Group Ltd Reports 9-Month 2025 Results — 6-K · Dec 2, 2025 Risk: low
NewGenIvf Group Limited filed a Form 6-K on December 2, 2025, reporting its nine-month results for 2025. The company, formerly known as ASPAC I Mini Acquisition
6-K Filing — 6-K · Nov 25, 2025
6-K Filing — 6-K · Nov 10, 2025
6-K Filing — 6-K · Nov 5, 2025
NewGenIvf Group Ltd. Reports Interim Results for H1 2025 — 6-K · Oct 9, 2025 Risk: low
NewGenIvf Group Limited (NewGen) has filed its Form 6-K for October 2025, reporting its unaudited interim results for the six months ended June 30, 2025. The fi
NewGenIvf Group Ltd. Announces 1-for-5 Reverse Stock Split — 6-K · Jul 28, 2025 Risk: medium
NewGenIvf Group Limited announced a one-for-five reverse stock split, effective August 4, 2025. This action aims to increase the per-share market price of the C
NewGenIvf Group Ltd Files July 2025 6-K Report — 6-K · Jul 21, 2025 Risk: low
NewGenIvf Group Limited filed a Form 6-K on July 21, 2025, reporting for the month of July 2025. The filing includes a press release as Exhibit 99.1. The compan
NewGenIvf Completes Fifth Debt Financing Tranche — 6-K · Jul 16, 2025 Risk: medium
NewGenIvf Group Limited announced on July 16, 2025, the completion of the fifth tranche of its debt financing. This follows the terms of a Securities Purchase A
NewGenIvf Group Ltd Amends Articles to Increase Share Capital — 6-K · Jul 7, 2025 Risk: low
NewGenIvf Group Limited announced on July 4, 2025, that its Board of Directors approved an amendment to its memorandum and articles of association to increase t
NewGenIvf Group Ltd Files July 2025 6-K Report — 6-K · Jul 1, 2025 Risk: low
NewGenIvf Group Ltd filed a Form 6-K on July 1, 2025, reporting for the month of July 2025. The filing includes a press release as Exhibit 99.1. The company, fo
NewGenIvf Share Count Surges Post-Prospectus — 6-K · Jun 20, 2025 Risk: medium
NewGenIvf Group Limited reported on June 20, 2025, that its total issued and outstanding shares have increased to 4,324,565. This includes 4,304,037 Class A ord
NewGenIvf Group to Present at Emerging Growth Conference — 6-K · Jun 17, 2025 Risk: low
NewGenIvf Group Limited will present at the Emerging Growth Conference on June 18, 2025, to provide updates on its digital asset portfolio. This online event of
NewGenIvf Group Ltd Closes Debt Financing Initial Closing — 6-K · Jun 4, 2025 Risk: medium
On June 3, 2025, NewGenIvf Group Limited completed the initial closing of its debt financing. This transaction is part of the Securities Purchase Agreement prev
NewGenIvf Group Ltd Files June 2025 6-K Report — 6-K · Jun 2, 2025 Risk: low
NewGenIvf Group Limited filed a Form 6-K on June 2, 2025, reporting for the month of June 2025. The filing indicates the company is a foreign private issuer and
NewGenIVF Group Ltd Files 20-F/A Amendment — 20-F/A · May 15, 2025 Risk: medium
NewGenIVF Group Ltd filed an amendment (20-F/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as ASPAC I Mini Ac
NewGenIvf Group Ltd. Announces 1-for-10 Reverse Stock Split — 6-K · Apr 29, 2025 Risk: medium
NewGenIvf Group Limited announced a one-for-ten reverse stock split of its issued and unissued shares, effective at 12:01 a.m. ET on Monday, May 5, 2025. This a
NewGenIVF Group Ltd Files 2024 Annual Report — 20-F · Apr 22, 2025 Risk: medium
NewGenIVF Group Ltd filed its annual report (Form 20-F) for the fiscal year ended December 31, 2024. The company, previously known as ASPAC I Mini Acquisition C
NewGenIvf Group Approves Reverse Stock Split — 6-K · Apr 16, 2025 Risk: low
On April 15, 2025, NewGenIvf Group Limited's Board of Directors approved a reverse stock split for all issued and unissued shares, including Class A ordinary sh
NewGenIvf Director Resigns from Board and Committees — 6-K · Apr 11, 2025 Risk: low
NewGenIvf Group Limited announced the resignation of director Mr. Yip Eng Jeremy Foo, effective April 4, 2025. Mr. Foo stepped down from the Board of Directors,
NewGenIvf Group Ltd. Announces Securities Purchase Agreement — 6-K · Apr 3, 2025 Risk: medium
On April 1, 2025, NewGenIvf Group Limited entered into a Securities Purchase Agreement with certain investors (the "Buyers") to sell shares. The agreement inclu
NewGenIvf Group Ltd Files February 2025 6-K Report — 6-K · Feb 20, 2025 Risk: low
NewGenIvf Group Limited filed a Form 6-K on February 20, 2025, reporting for the month of February 2025. The filing includes a press release as Exhibit 99.1. Th
NewGenIvf Group Ltd Approves Reverse Stock Split — 6-K · Jan 31, 2025 Risk: medium
NewGenIvf Group Ltd announced on January 21, 2025, that its Board of Directors approved a reverse stock split for all issued and unissued shares, including Clas
NewGenIvf Group Ltd Files January 2025 6-K Report — 6-K · Jan 21, 2025 Risk: low
NewGenIvf Group Limited filed a Form 6-K on January 21, 2025, reporting for the month of January 2025. The filing includes a press release as Exhibit 99.1. The
SC 13G Filing — SC 13G · Dec 5, 2024
NewGenIvf Appoints Independent Director to Board — 6-K · Dec 3, 2024 Risk: low
NewGenIvf Group Limited announced on November 29, 2024, the appointment of Tam, Chun Wa as an independent director to its Board of Directors. Mr. Tam has also b
NewGenIvf Group Ltd Files November 2024 6-K Report — 6-K · Nov 22, 2024 Risk: low
NewGenIvf Group Limited filed a Form 6-K on November 22, 2024, reporting for the month of November 2024. The filing includes a press release as Exhibit 99.1. Th
NewGenIvf Group Ltd Files 6-K Report — 6-K · Nov 18, 2024 Risk: low
NewGenIvf Group Limited filed a Form 6-K on November 18, 2024, reporting information for the month of November 2024. The filing includes a press release as Exhi
NewGenIvf Completes Third Debt Financing Tranche — 6-K · Nov 15, 2024 Risk: medium
NewGenIvf Group Limited announced on November 11, 2024, the completion of the third tranche of its debt financing. This follows the terms of a Securities Purcha
SC 13G Filing — SC 13G · Nov 13, 2024
SC 13G Filing — SC 13G · Oct 10, 2024
NewGenIvf Appoints New Auditor for FY2024 — 6-K · Sep 4, 2024 Risk: low
NewGenIvf Group Limited announced on September 3, 2024, the appointment of J&S Associate as its independent registered public accounting firm for the fiscal yea
NewGenIvf Completes Second Debt Financing Tranche — 6-K · Aug 30, 2024 Risk: medium
NewGenIvf Group Limited announced on August 28, 2024, the completion of the second tranche of its debt financing. This follows the terms of a Securities Purchas
NewGenIVF Group Ltd Files 2023 Annual Report — 20-F · Aug 20, 2024 Risk: medium
NewGenIVF Group Ltd filed its annual report on Form 20-F for the fiscal year ended December 31, 2023. The company, formerly known as ASPAC I Mini Acquisition Co
NewGenIvf Group Ltd. Announces Securities Purchase Agreement — 6-K · Aug 16, 2024 Risk: medium
On August 7, 2024, NewGenIvf Group Limited entered into a Securities Purchase Agreement with certain investors, referred to as the "Buyers," to sell securities.
NewGenIvf Group Ltd Files 6-K Report — 6-K · Jun 3, 2024 Risk: low
NewGenIvf Group Limited, formerly ASPAC I Mini Acquisition Corp., filed a Form 6-K on June 3, 2024. The filing includes a press release as Exhibit 99.1. The com
NewGenIvf Receives Nasdaq Minimum Bid Price Deficiency Letter — 6-K · May 28, 2024 Risk: medium
NewGenIvf Group Limited received a deficiency letter from Nasdaq on May 24, 2024, regarding a minimum market value of publicly held shares. The company is requi
NewGenIvf Group Ltd Explores Acquisition, Plans $1.5M Private Placement — 6-K · Apr 22, 2024 Risk: medium
On April 17, 2024, NewGenIvf Group Limited entered into a non-binding term sheet with European Wellness Investment Holdings Limited (EWIHL) for the potential ac
Siu Wing Fung Alfred Files 13D for NewGenIvf Group Ltd — SC 13D · Apr 10, 2024 Risk: medium
On April 3, 2024, Siu Wing Fung Alfred filed a Schedule 13D regarding NewGenIvf Group Ltd. This filing indicates a change in beneficial ownership of the company
NewGenIVF Group Ltd Files 20-F Report — 20-F · Apr 9, 2024 Risk: low
NewGenIvf Group Ltd (NIVFW) filed a Foreign Annual Report (20-F) with the SEC on April 9, 2024. NewGenIVF Group Ltd filed a 20-F report on April 9, 2024. The co
NewGenIvf Group Ltd Files 6-K Report — 6-K · Apr 4, 2024 Risk: low
NewGenIvf Group Limited, formerly A SPAC I Mini Acquisition Corp., filed a Form 6-K on April 4, 2024. The filing is a report of a foreign private issuer for the
SC 13G/A Filing — SC 13G/A · Feb 22, 2024

Risk Profile

Risk Assessment: Of NIVFW's 34 recent filings, 0 were flagged as high-risk, 16 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Wing Fung Alfred Siu Nam
Wing Fung Alfred Siu
Yip Eng Jeremy Foo
Tam, Chun Wa
Siu Wing Fung Alfred
Wai Lam Tina Fong

Top Tags

foreign-private-issuer (9) · corporate-action (8) · 6-K (5) · sec-filing (5) · reverse-stock-split (4) · regulatory-filing (4) · debt-financing (4) · financing (4) · annual-report (3) · filing (3)

Key Numbers

Reporting Period: Nine-Month 2025 — Results for the first nine months of 2025 are detailed in Exhibit 99.1.
Reverse Stock Split Ratio: 1-for-5 — The company is consolidating shares at this ratio.
Filing Date: 20250721 — The date the report was officially filed with the SEC.
Total Shares Outstanding: 4.32M — Represents a significant increase from the previous disclosure.
Previous Shares Outstanding: 1.05M — Disclosed in the June 3, 2025 prospectus.
Fiscal Year End: 2024 — The report covers the fiscal year ending December 31, 2024.
SEC File Number: 001-42004 — Identifies the company's filing with the SEC.
Private Placement: $1.5M — Capital to be raised to fund operations and potential acquisitions.
Class A ordinary shares outstanding: 10,149,386 — As of April 3, 2024
Warrants outstanding: 8,319,988 — As of April 3, 2024
Date of name change: 20230614 — From ASPAC I Mini Acquisition Corp.

Related Companies

NEOV

Frequently Asked Questions

What are the latest SEC filings for Newgenivf Group LTD (NIVFW)?

Newgenivf Group LTD has 41 recent SEC filings from Feb 2024 to Dec 2025, including 32 6-K, 3 20-F, 3 SC 13G. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of NIVFW filings?

Across 41 filings, the sentiment breakdown is: 1 bearish, 39 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Newgenivf Group LTD SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Newgenivf Group LTD (NIVFW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Newgenivf Group LTD?

Financial highlights for Newgenivf Group LTD are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for NIVFW?

The investment thesis for NIVFW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Newgenivf Group LTD?

Key executives identified across Newgenivf Group LTD's filings include Wing Fung Alfred Siu Nam, Wing Fung Alfred Siu, Yip Eng Jeremy Foo, Tam, Chun Wa, Siu Wing Fung Alfred and 1 others.

What are the main risk factors for Newgenivf Group LTD stock?

Of NIVFW's 34 assessed filings, 0 were flagged high-risk, 16 medium-risk, and 18 low-risk.

What are recent predictions and forward guidance from Newgenivf Group LTD?

Forward guidance and predictions for Newgenivf Group LTD are extracted from SEC filings as they are enriched.